|
|
1700 Kraft Drive, Suite 2400
Blacksburg, VA 24060 USA
phone:540 961-5559
fax:
|
|
| Symbol |
Private |
| Founded |
2003 |
| Employees |
20 |
|
|
| www.revivicor.com
|
|
| Research Sector |
Healthcare Services |
|
 |
| Summary Description |
| Xenografts and Tolerance Technologies for Applications in Diabetes and Whole Organ Transplantation |
|
| Management |
| David Ayares, Ph.D., Chief Executive Officer, Chief Scientific Officer; Karla Gragg, Director of Human Resources and Administration; John Bianchi, VP of Product Development |
| |
|
|
| |
|
| Keywords |
| regenerative medicine, whole organ transplant, diabetes, xenotransplantation, stem cells |
|
|
|
| Description |
|
Revivicor's focus is the commercialization of treatments for diabetes and whole organ transplantation, developed from the significant advances made in the fields of xenografts and tolerance technologies, which are core competencies of Revivicor. In addition to the regenerative medicine portfolio, Revivicor also has a rapidly progressing research program for the production of polyclonal antibodies in livestock. |
|
|
| Funding |
| Revivicor's investors are the University of Pittsburgh Medical Center (UPMC) Health System, Highmark Health Ventures Investment Fund, L.P., and Fujisawa Investments for Entrepreneurship, |
|
| Status |
| Revivicor's existing capital is focused on late stage programs, including pivotal animal and human clinical studies with pancreatic islet cells and whole organs. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members